Supernus Pharmaceuticals, Inc.
Symbol: SUPN (NASDAQ)
45.47
▼ (-2.55%) -1.190
Company Description:
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
Key Stats
- Today's Open: $46.47
- Today's High: $46.67
- Today's Low: $40.121
- Today's Volume: 415.08K
- Yesterday Close: $46.66
- Yesterday High: $46.72
- Yesterday Low: $45.87
- Yesterday Volume: 470.46K
- Last Min Volume: 21
- Last Min High: $45.47
- Last Min Low: $45.47
- Last Min VWAP: $45.47
Company Profile
- Name: Supernus Pharmaceuticals, Inc.
- Website: https://www.supernus.com
- Listed Date: 2012-05-01
- Location: ROCKVILLE, MD
- Market Status: Active
- CIK Number: 0001356576
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $2.55B
- Round Lot: 100
- Outstanding Shares: 56.07M
- Asset Type: CS
RECENT FILINGS FOR SUPN
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-12 | 4 | View |
| 2025-09-12 | 4 | View |
| 2025-09-12 | 144 | View |
| 2025-09-09 | 4 | View |
| 2025-09-08 | 4 | View |
| 2025-09-08 | 144 | View |
| 2025-09-05 | 144 | View |
| 2025-08-29 | 4 | View |
| 2025-08-29 | 4 | View |
| 2025-08-28 | 144 | View |
| 2025-08-27 | 4 | View |
| 2025-08-27 | 4 | View |
| 2025-08-27 | 4 | View |
| 2025-08-27 | 4 | View |
| 2025-08-27 | 144 | View |
| 2025-08-26 | 4 | View |
| 2025-08-26 | 4 | View |
| 2025-08-26 | 4 | View |
| 2025-08-25 | 144 | View |
| 2025-08-25 | 144 | View |
Latest News on SUPN